Contraception with progestagens in systemic lupus erythematosus

Area of Science:

• Reproductive Medicine
• Immunology
• Pharmacology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease affecting women of reproductive age.
• Contraception is crucial for women with SLE to manage pregnancy risks and disease activity.
• Hormonal contraceptives, particularly progestagens, require careful evaluation in SLE patients due to potential disease interactions.

Purpose of the Study:

• To evaluate the efficacy and tolerance of progestagen-only contraceptives in women with SLE.
• To compare the impact of norethisterone enanthate and levonorgestrel on SLE disease activity.
• To assess the contraceptive effectiveness and side effect profile of these agents in this population.

Main Methods:

• A comparative study involving 10 patients receiving intramuscular norethisterone enanthate (200 mg) and 15 patients receiving oral levonorgestrel (0.03 mg/day).
• A control group of 18 patients with SLE not using hormonal contraception was included for comparison.
• Disease activity was monitored, and contraceptive efficacy (pregnancy rates) and side effects (bleeding patterns) were recorded.

Main Results:

• No statistically significant difference in the rate of active SLE episodes was observed between the progestagen groups and the control group (p = ns).
• Both norethisterone enanthate and levonorgestrel demonstrated 100% contraceptive efficacy, with no pregnancies reported during the study.
• Intermenstrual bleeding was a notable side effect, leading to discontinuation in 30% of patients.

Conclusions:

• Progestagen-only contraceptives, including norethisterone enanthate and levonorgestrel, appear to be safe and effective options for women with SLE.
• These agents did not exacerbate SLE disease activity in the studied population.
• While effective for contraception, careful counseling regarding potential bleeding irregularities is warranted for patients with SLE considering these methods.